乌斯图索拉特E和11α-氧-乌斯图索拉特E通过调节PI3K/AKT/mTOR和p-53通路,诱导癌细胞系的亡
Mewlude Rehmutulla1, Sitian Zhang1, Jie Yin1
1Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Chinese journal of natural medicines
|March 23, 2025
概括
新的天然化合物乌斯图索拉特E (UE) 和11α--乌斯图索拉特E (HUE) 显示出强大的抗癌活性. 这些化合物有效地抑制癌细胞生长并诱导细胞亡,为新药开发提供了潜力.
科学领域:
- 自然产品化学 自然产品化学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症对全球健康和经济造成重大负担,预测显示到2040年,癌症病例将大幅增加.
- 新型抗癌疗法的开发对于对抗不断增加的癌症发病率至关重要.
- 自然产品 (NPs) 是发现和开发新抗癌药物的重要来源.
研究的目的:
- 为了识别和描述来自真菌Aspergillus calidoustus TJ403-EL05.05的具有抗癌潜力的新化合物.
- 调查乌斯图酸E (UE) 和其模拟物11α-基-乌斯图酸E (HUE) 的抗瘤活性和作用机制.
主要方法:
- 从Aspergillus calidoustus中分离并阐明UE和HUE的结构.
- 在实验室中对抗人类胃癌 (AGS) 和清细胞癌 (786-O) 细胞系的抗瘤活性进行评估.
- 分析包括诱导DNA损伤,在G2/M阶段停止细胞循环和亡等机制.
主要成果:
- UE和HUE都显著抑制了AGS和786-O癌细胞的增殖和殖民地形成.
- 这些化合物在瘤细胞的G2/M阶段诱导了不可逆转的DNA损伤和细胞周期停止.
- 发现UE和HUE可以有效地诱导癌细胞的亡.
结论:
- 这项研究提出了关于UE和HUE抗癌作用和机制的首份报告.
- 这些发现表明,UE和HUE具有显著的抗瘤特性.
- 作为新型抗癌药物开发的化合物,HUE和UE显示出前景.
相关概念视频
The Intrinsic Apoptotic Pathway
5.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.8K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


